dr. overman on distinctions between regorafenib and tas-102 in crc
Published 4 years ago • 147 plays • Length 1:28Download video MP4
Download video MP3
Similar videos
-
1:16
dr. eng on roles of regorafenib and tas-102 in crc treatment
-
1:12
dr. lenz on choosing between regorafenib and tas-102 in crc
-
1:50
dr. bekaii-saab on sequencing regorafenib and tas-102 in crc
-
1:27
dr. overman on ongoing research with immunotherapy in mss crc
-
1:35
dr. lockhart on next steps for regorafenib and tas-102 in mcrc
-
0:57
choosing between tas-102 and regorafenib in colorectal cancer
-
7:54
regorafenib vs tas-102 salvage therapy
-
1:16
dr. bekaii-saab on tas-102 and regorafenib in mcrc
-
2:15
dr. overman discusses redos study in mcrc
-
2:24
dr. bekaii saab compares toxicities of regorafenib and tas-102 in colorectal cancer
-
1:05
dr. corcoran on the utility of regorafenib in crc
-
1:46
dr. overman on investigational targeted therapies in mcrc
-
1:39
dr. hochster on the safety analysis of tas-102 in crc and gastric/gej cancer
-
0:50
dr. wu on possible combinations with tas-102 in crc
-
0:20
copy of dr. bekaii-saab on tas-102 and regorafenib in mcrc
-
2:13
later-line treatment for mcrc: regorafenib or tas-102?
-
1:29
dr. overman on tailoring approaches to molecular subsets in mcrc
-
1:22
dr. overman on potential applications of ctdna in colorectal cancer
-
1:23
dr. bekaii-saab on benefits associated with regorafenib or tas-102 for crc